Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $11.6 million.

  • Northwest Biotherapeutics' Cash from Financing Activities fell 53.36% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year decrease of 647.33%. This contributed to the annual value of $56.8 million for FY2024, which is 763.3% up from last year.
  • Northwest Biotherapeutics' Cash from Financing Activities amounted to $11.6 million in Q3 2025, which was down 53.36% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Cash from Financing Activities ranged from a high of $23.7 million in Q4 2021 and a low of $3.9 million during Q1 2022
  • Moreover, its 5-year median value for Cash from Financing Activities was $11.7 million (2025), whereas its average is $12.4 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Cash from Financing Activities plummeted by 6370.61% in 2021 and then skyrocketed by 22096.94% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Cash from Financing Activities stood at $23.7 million in 2021, then plummeted by 52.04% to $11.4 million in 2022, then increased by 26.99% to $14.4 million in 2023, then grew by 10.59% to $15.9 million in 2024, then fell by 27.5% to $11.6 million in 2025.
  • Its Cash from Financing Activities was $11.6 million in Q3 2025, compared to $12.4 million in Q2 2025 and $11.7 million in Q1 2025.